Serotonin Biosynthesis as a Predictive Marker of Serotonin Pharmacodynamics and Disease-Induced Dysregulation
Welford, R.W.; Vercauteren, M.; Trébaul, A., et al.
In a metabolomics-based tracer study, Welford and colleagues used 13C-labeled tryptophan as an oral tracer to measure/quantify the biosynthesis and metabolism of serotonin in rats. Here, the flux and pharmacokinetics of serotonin pathway metabolites were measured in various tissues by LC-MRM/MS. The pharmacodynamic effects of serotonin synthesis inhibition in vivo were also investigated. This study should help facilitate the development of improved serotonin synthesis inhibitors, which could have therapeutic potential in diseases such as lung fibrosis, osteoporosis, and obesity.
Articles
- SWATH-based Proteomics Identified Carbonic Anhydrase 2 as a Potential Diagnosis Biomarker for Nasopharyngeal Carcinoma
- Serotonin Biosynthesis as a Predictive Marker of Serotonin Pharmacodynamics and Disease-Induced Dysregulation
- Comparative Analysis of INLIGHT™-labeled Enzymatically Depolymerized Heparin by Reverse-phase Chromatography and High-performance Mass Spectrometry
- 13C Metabolic Flux Analysis of Acetate Conversion to Lipids by Yarrowia lipolytica
- Historical and Contemporary Stable Isotope Tracer Approaches to Studying Mammalian Protein Metabolism
